News Europe Maltese Medical Cannabis To Boost Exports

Maltese Medical Cannabis To Boost Exports

-

THE Maltese approach to cannabis is set to see its total value of exports increase by 30%.

Malta decriminalised cannabis in 2013, and legalised medical cannabis in March, 2018 and has since made significant strides in becoming a leading player in the emerging European market.

In an interview with Health Europa in 2019 Marion Zammit of Malta Enterprise confirmed over 20 projects had been approved.

She said these included Canadian, Australian and US companies. In June, last year Aphria’s Malta subsidiary, ASG Pharma, received an import license from The Malta Medicines Authority.

Malta Enterprise has granted Canadian firm Aurora approval for a seed-to-pharma operation in partnership with local firm Cherubino.

Australian firm MGC Pharmaceuticals signed a deal with the Maltese government which will see it create an € 11m medical cannabis manufacturing plant.

Whilst Toronto firms MPXI and Supreme and US firm Columbia Care, are also amongst the 20 approved projects. 

Ms Zammit went on to say that once all approved projects are in operational it ‘will supplement exports by an additional 30%’, adding: “We are creating a new sub-niche in the manufacturing sector and this in turn will make our economy more robust.”

Malta, a small Mediterranean island with a population of less than half a million, has a strong advanced manufacturing and pharmaceutical base.

It promotes itself as being in an ‘ideal geographic location capable of  bridging continents’, with English being the language of choice for business. 

MGC Pharmaceuticals founder and director Nativ Segev said its move allows it to be a ‘part of Malta’s drive to become a beacon in Europe for the growth and development of this industry’. 

Economy Minister Chris Cardona said that as the first country in the EU to provide a regulatory framework for medical cannabis ‘it has been able to attract the best investment to our country, with the sector already contributing to economic growth’.

Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Compliant CBD Companies Call For Crackdown On UK’s Novel Food ‘Refuseniks’

AFTER cumulatively spending tens of millions of pounds on Novel Food compliance many UK CBD companies may be left...

Six Companies Chosen to Supply Products – Free Of Charge – To France’s First Medical Cannabis Trial

SIX companies have seen their products selected for use in the French medical cannabis trial for 3,000 patients which...

Colombian Producer Delivers Its First ‘Cost-Effective’ Medical Cannabis Export To Australia

COLOMBIAN producer Foliumed has completed its first export to Australia as it looks to support the country’s fast-growing medical...

Children’s Dutch Epilepsy Cannabis Medicines Will Be Made In The UK To Overcome Import Impasse

A PERMANENT solution to the import impasse on children’s epilepsy cannabis medication has emerged with the Dutch manufacturer set...

Amazon Enters CBD Retail Market – But Only In One Country

GLOBAL on-line retail giant Amazon is dipping its toes into the CBD market with the first ever products now...

The UK Medical Cannabis Industry Can – And Does – Provide Epilepsy Medicines For Children In Post-Brexit Britain

Pierre Van Weperen of Grow Pharma on the post-Brexit issue surrounding the import of epilepsy cannabis medicines into the...

Must read

Compliant CBD Companies Call For Crackdown On UK’s Novel Food ‘Refuseniks’

AFTER cumulatively spending tens of millions of pounds on...

Colombian Producer Delivers Its First ‘Cost-Effective’ Medical Cannabis Export To Australia

COLOMBIAN producer Foliumed has completed its first export to...

You might also likeRELATED
Recommended to you